Literature DB >> 1430361

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study.

J el-On1, S Halevy, M H Grunwald, L Weinrauch.   

Abstract

BACKGROUND: A controlled study of the efficacy of topical paromomycin sulfate (PR) and methylbenzethonium chloride (MBCl) in cutaneous leishmaniasis (CL) has not yet been performed.
OBJECTIVE: The therapeutic effect of an ointment containing 15% PR and either 12% or 5% MBCl (15/12 or 15/5 P-ointment) on patients suffering from Old World CL was examined in a randomized, double-blind, cross-over study.
METHODS: Thirty-nine patients with Old World CL caused by Leishmania major were treated topically, twice daily, for 10 to 20 days with 15/12 or 15/5 P-ointment and 10 to 20 days with a placebo ointment to achieve a total of 30 days of treatment in all groups.
RESULTS: In the P-ointment-treated groups, 74.2% (29 of 39 patients) of the patients were cured versus 26.6% (4 of 15 patients) in the placebo-treated group. Little difference was found between the 15/12 and 15/5 P-ointment groups.
CONCLUSION: In most of the patients treated with the active ingredients, total elimination of the parasites was achieved within the first 10 days of treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430361     DOI: 10.1016/0190-9622(92)70175-f

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  23 in total

Review 1.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

Review 2.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 3.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.

Authors:  Adrienne J Showler; Andrea K Boggild
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

Review 5.  Parasitic skin infections in the elderly: recognition and drug treatment.

Authors:  H H Tan; C L Goh
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 6.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

Review 7.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

8.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

9.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Ribosomes of Leishmania are a target for the aminoglycosides.

Authors:  M Maarouf; F Lawrence; S L Croft; M Robert-Gero
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.